204 related articles for article (PubMed ID: 22053108)
21. EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms.
Ueda T; Sanada M; Matsui H; Yamasaki N; Honda ZI; Shih LY; Mori H; Inaba T; Ogawa S; Honda H
Leukemia; 2012 Dec; 26(12):2557-60. PubMed ID: 22733077
[No Abstract] [Full Text] [Related]
22. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.
Kaito S; Iwama A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374737
[TBL] [Abstract][Full Text] [Related]
23. JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.
Celik H; Koh WK; Kramer AC; Ostrander EL; Mallaney C; Fisher DAC; Xiang J; Wilson WC; Martens A; Kothari A; Fishberger G; Tycksen E; Karpova D; Duncavage EJ; Lee Y; Oh ST; Challen GA
Cancer Cell; 2018 Nov; 34(5):741-756.e8. PubMed ID: 30423295
[TBL] [Abstract][Full Text] [Related]
24. The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.
Meggendorfer M; Jeromin S; Haferlach C; Kern W; Haferlach T
Haematologica; 2018 May; 103(5):e192-e195. PubMed ID: 29700173
[No Abstract] [Full Text] [Related]
25. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
Grand FH; Hidalgo-Curtis CE; Ernst T; Zoi K; Zoi C; McGuire C; Kreil S; Jones A; Score J; Metzgeroth G; Oscier D; Hall A; Brandts C; Serve H; Reiter A; Chase AJ; Cross NC
Blood; 2009 Jun; 113(24):6182-92. PubMed ID: 19387008
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
Jiao L; Liu X
Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
[TBL] [Abstract][Full Text] [Related]
27. Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding.
Chen S; Jiao L; Shubbar M; Yang X; Liu X
Mol Cell; 2018 Mar; 69(5):840-852.e5. PubMed ID: 29499137
[TBL] [Abstract][Full Text] [Related]
28. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.
Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL
Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897
[TBL] [Abstract][Full Text] [Related]
29. Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Rumi E; Cazzola M
Haematologica; 2014 Nov; 99(11):1650-2. PubMed ID: 25420280
[No Abstract] [Full Text] [Related]
30. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
Zoabi M; Sadeh R; de Bie P; Marquez VE; Ciechanover A
Biochem Biophys Res Commun; 2011 May; 408(3):393-8. PubMed ID: 21513699
[TBL] [Abstract][Full Text] [Related]
31. Polycomb recruitment at the Class II transactivator gene.
Boyd NH; Morgan JE; Greer SF
Mol Immunol; 2015 Oct; 67(2 Pt B):482-91. PubMed ID: 26283540
[TBL] [Abstract][Full Text] [Related]
32. Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing.
Schoeftner S; Sengupta AK; Kubicek S; Mechtler K; Spahn L; Koseki H; Jenuwein T; Wutz A
EMBO J; 2006 Jul; 25(13):3110-22. PubMed ID: 16763550
[TBL] [Abstract][Full Text] [Related]
33. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.
Makishima H; Jankowska AM; Tiu RV; Szpurka H; Sugimoto Y; Hu Z; Saunthararajah Y; Guinta K; Keddache MA; Putnam P; Sekeres MA; Moliterno AR; List AF; McDevitt MA; Maciejewski JP
Leukemia; 2010 Oct; 24(10):1799-804. PubMed ID: 20724984
[No Abstract] [Full Text] [Related]
34. Developmental regulation of Suz 12 localization.
de la Cruz CC; Fang J; Plath K; Worringer KA; Nusinow DA; Zhang Y; Panning B
Chromosoma; 2005 Aug; 114(3):183-92. PubMed ID: 15986205
[TBL] [Abstract][Full Text] [Related]
35. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
36. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies.
Gómez-Seguí I; Makishima H; Jerez A; Yoshida K; Przychodzen B; Miyano S; Shiraishi Y; Husseinzadeh HD; Guinta K; Clemente M; Hosono N; McDevitt MA; Moliterno AR; Sekeres MA; Ogawa S; Maciejewski JP
Leukemia; 2013 Sep; 27(9):1943-6. PubMed ID: 23765226
[No Abstract] [Full Text] [Related]
37. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Zamora L; Xandri M; Garcia O; Marcé S; Xicoy B; Granada I; Navarro JT; Millá F
Am J Clin Pathol; 2012 Apr; 137(4):677-8. PubMed ID: 22431549
[No Abstract] [Full Text] [Related]
38. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
Zhu K; Du D; Yang R; Tao H; Zhang H
Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
[TBL] [Abstract][Full Text] [Related]
39. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms.
Chase A; Score J; Lin F; Bryant C; Waghorn K; Yapp S; Carreno-Tarragona G; Aranaz P; Villasante A; Ernst T; Cross NCP
Leukemia; 2020 Dec; 34(12):3206-3214. PubMed ID: 32322039
[TBL] [Abstract][Full Text] [Related]
40. Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity.
Majewski IJ; Blewitt ME; de Graaf CA; McManus EJ; Bahlo M; Hilton AA; Hyland CD; Smyth GK; Corbin JE; Metcalf D; Alexander WS; Hilton DJ
PLoS Biol; 2008 Apr; 6(4):e93. PubMed ID: 18416604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
